Former senior executive at Becton Dickinson and Co
- Key trends and developments in the infusion pumps and injectables manufacturing space
- Becton Dickinson’s (NYSE: BDX) manufacturing capacity to meet global supply shortages
- Historical M&A integrations and tuck-in acquisition opportunities to expand informatics and AI portfolios
- Becton Dickinson’s competitive positioning amid Alaris infusion pump recall
- 2023 outlook and strategies to drive revenue growth
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.